Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 75/100

Termination Rate

20.0%

1 terminated out of 5 trials

Success Rate

0.0%

-86.5% vs benchmark

Late-Stage Pipeline

20%

1 trials in Phase 3/4

Results Transparency

0%

1 of 0 completed with results

Key Signals

1 with results0

Data Visualizations

Phase Distribution

5Total
Early P 1 (1)
P 1 (2)
P 2 (1)
P 3 (1)

Trial Status

Terminated1
Active Not Recruiting1
Withdrawn1
Unknown1
Recruiting1

Clinical Trials (5)

Showing 5 of 5 trials
NCT04482933Phase 2Withdrawn

HSV G207 With a Single Radiation Dose in Children With Recurrent High-Grade Glioma

NCT06193174Phase 1Terminated

Re-Administration of C134 in Patients With Recurrent GBM (C134-HSV-1)

NCT03657576Phase 1Active Not Recruiting

Trial of C134 in Patients With Recurrent GBM

NCT04135807Early Phase 1Recruiting

Implantable Microdevice In Primary Brain Tumors

NCT03633552Phase 3Unknown

Efficacy of Two Temozolomide Regimens in Adjuvant Treatment of Patients With Brain High Grade Glioma

Showing all 5 trials

Research Network

Activity Timeline